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Joshua Lederberg
President

Because it is my first annual report as president, this writing is a
panoramic personal reflection of my views of The Rockefeller Uni
versity. This first year has remarkably confirmed my optimistic
expectations about the University. My greatest surprise was to have
experienced so few surprises about the kind of place it is and the kind
of people who work here.
Three years ago, The Rockefeller University- founded in 190 I
as The Rockefeller Institute for Medical Research-observed its 75th
anniversary. A theme of the celebration was the continuity of the
tradition and achievement which marked the transition from Institute
to University. As I noted in my inaugural remarks last October, the
record of that anniversary reflects the success of the transition and
also dramatizes the opportunities that drew me here: to conserve and
enhance the most vital tradition of biomedical research to be found
anywhere today.
In keeping with the vitality of this tradition, many of the things I
write will not now, nor in the future, appear as radical innovations.
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It is my hope that, if events allow, they may bear repeating several

years from now. I welcome the opportunity to define, in the light of
contemporary circumstances, the spirit in which I approach my new
responsibilities.
The substantial scope, simple structure,'and coherent goals of this
University offer a unique challenge to scientific leadership. Certainly
today we have a broader conception than existed in 1901 of the
scientific foundation needed for an understanding of human biology.
Thanks, in large part, to the inspiration of the late Detlev W. Bronk,
the University has incorporated the behavioral sciences and broad
ened the base of the physical sciences on this campus. It was President
Bronk who brought Carl Pfaffmann here to develop the University's
strong program of behavioral studies. Dr. Pfaffman, who retired this
year as vice president, continues to head one of our physiological
psychology laboratories. The distinction of our physics and mathe
matics faculties and their positions at the international forefront in
their disciplines have added a stimulating new dimension to the
intellectual life of this scientific community. But the scientific pro
grams of the University, for all the diversity of fundamental and
clinical research carried out in its 60 independent laboratories, remain
firmly based on the biomedical sciences and sharply tuned to the
protection and improvement of the health of the human species.
In leading institutions that have multiple concerns and aims, as is
typical of many larger universities, presidents are preoccupied with
negotiating compromises between disparate sets of values. This is a
leadership challenge of a rather different kind and implies a strong
political role. But here basic political questions are, in a sense, already
settled: first by the University's coherence of goals, and second by its
fundamental structure.
Our University is unusual in not being divided into schools with
competing interests and distinctive concerns such as law, medicine, or
engineering. We have no division of undergraduate studies competing
for attention and resources for other purposes. Nor do we have
academic departments which carve out sovereign intellectual territo
ries. Instead, we are organized simply into individual laboratories,
each led by a senior investigator. The work of the laboratory is, of
course, shared by a varying number of junior faculty, postdoctoral
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fellows, graduate students, and technicians.
The usual departmental structure aggregates specialists within
fairly closely bounded areas, within which intensive conceptual effort
is supported. This style of organizational structure may be indispens
able for the management of teaching or service functions. Yet it tends
to isolate academic colleagues from those in other disciplines and
hinders novel and boundary lines of research. These are very real
obstacles to certain kinds of innovation.
Our University could have had departments of physiology or
biochemistry or pharmacology or pathology. But the conscious re
nunciation of this pattern of organization, from the initial founding,
has fostered innovative interdisciplinary research. (The continuous
momentum of the scientific and educational work of the University
during the past year is described in the publication Scientific and
Educational Programs.) Some of the brief sketches of current research
accompanying this report illustrate the quality of such interaction,
which can start with a conversation in the cafeteria, a short stroll from
one building to another on our compact 15-acre campus, or in the
mind of a clinical researcher sensitized by continued laboratory
contact to think "chemically" about a medical problem. It is no
accident that it is possible here for an organic chemist or a pharma
cologist with a Ph.D. to be involved in clinical investigation of the
highest quality. It is equally easy for a behavioral scientist to collab
orate with a biochemist or a physiologist in uncovering the mecha
nisms underlying behavioral data gathered in field studies.
In addition, the University offers an opportunity for undistracted
research, which is appealing to scientists who, at some institutions,
might have to spend considerable time doing other things, useful and
important but not directly related to their research.
A Collegial Structure
A simile for this organization is that the president here functions like
the head of a single academic department with a regular faculty of
200 scientists. Now, whether 60 laboratories can report to one indi
vidual, and sustain an acceptable degree of managerial effectiveness,
raises questions that a beginning student of management will antici
pate. Yet this simple structure has, over the decades, stimulated a
continued on page 6
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Male Chaffinch and sound spectrogram of complete song.

Bird song, one of the most common and
delightful natural sounds on earth, is a
biologically important, complex form of
reproductive behavior used by the avian
male to attract and keep a mate and to
defend the territory where he lives, mates,
and nests. Peter Marler, head of the Uni
versity's Field Research Center at Mill
brook, N. Y., has found many parallels
between bird song and human language.
For one thing, probably all the Oscines songbirds, such as canaries, sparrows,
robins, and finches - learn to sing the
way humans learn to speak by listening to
and imitating others of their species. Birds
and human beings are the only creatures
known to learn the sounds they use to
exchange information.
For almost a decade, Fernando Notte
bohm, a colleague of Dr. Marler's, has col
laborated with members of several Uni-

versity laboratories in interdisciplinary
studies of songbird behavior, ranging
across anatomy, neurophysiology, and
biochemistry. Significant clues have
emerged on how the brains of songbirds
approach the task of vocal learning.
Bird song is produced by the syrinx, a
structure deep within the chest where the
two bronchial tubes from the lungs join
the trachea, or windpipe. In Oscines, the
syrinx has two sound sources, the internal
tympaniform membranes, which form part
of the medial wall of each bronchus. Air
rushes through the bronchi and past the
tympanic membranes, which vibrate rap
idly to produce sound. Pitch and loudness
are modulated by the syringeal muscles,
which set membrane tension and control
airflow. Each half of the syrinx is inner
vated by a branch of the hypoglossal
nerve.
When Dr. Nottebohm began his re
search, virtually nothing was known about
the neural pathways involved in song pro-
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duction. Using behavioral studies and an
atomical techniques, he and neuroanato
mist Christiana Leonard traced central
nervous pathways that control song in the
canary. They described discrete vocal con
trol areas in the brain where nerve path
ways related to song production interface
with centers for processing auditory infor
mation. A totally unexpected, but highly
significant, finding was that in songbirds,
as in humans, the left hemisphere of the
brain dominates vocal behavior. This was
the first reported non-human example of
hemispheric asymmetry, the concentra
tion of a specific function on one side of
the brain.
Another important discovery, by Dr.
Nottebohm and Arthur P. Arnold, was that
brain vocal control areas in male songbirds
are several times larger than in females.
This so-called sexual dimorphism seems
to be related to differences in behavior:
male birds learn songs by imitation and
sing profusely; females sing little, if at all.
When reported in 1976, this was the first
description of such a gross sexual differ
ence in a vertebrate brain.
There is a wide body of evidence that
in both humans and animals sexual be
havior is heavily influenced by steroid hor
mones secreted by the gonads. They stim
ulate such behavior by acting on nerve
cells in the brain. For instance, testoster
one, a male sex hormone, determines the
amount of singing done by canaries and
zebra finches. During the breeding season,
normal males sing a lot. Castrated males
sing very little, but this can be corrected
by administering testosterone. Using ra -:
dioactively tagged hormones, Dr. Arnold,
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with the help of Dr. Donald Pfaff and as
part of his thesis work in the Nottebohm
laboratory, discovered that some vocal
control stations in the songbird brain con
centrate testosterone in their cells. In par
ticular, the motoneurons which innervate
the syringeal muscles also are hormone
sensitive "target" cells.
Several years ago, Dr. Nottebohm
joined forces with Bruce McEwen's group
to see whether the anatomical and physi
ological findings on bird song could be
related more directly to biochemical ef
fects on behavior. Dr. McEwen's labora
tory group is seeking to learn how hor
mones interact biochemically with nerve
tissue to activate behavior.
Doctors Nottebohm and Ivan Lieber
burg established by test-tube experiments
that syringeal muscle also has testoster
one-sensitive cells. This suggests a direct
hormonal influence on song-control mus
cles. Experiments done with Doctors Vic
toria N. Luine and Cheryl Harding indicate
that testosterone is necessary for main
taining the levels of an enzyme in the
syringeal muscle that is important in neu
romuscular transmission. Clearly, the ef
fects of sex hormones on bird song occur
at multiple levels, from the brain to the
very muscles that modulate song.
Dr. Nottebohm believes that the study
of phenomena as disparate as hemispheric
dominance, sexual dimorphism, and hor
monal regulation of behavior is leading
him to the more difficult and fascinating
question of how learning affects brain
pathways. He is confident that the avian
brain, evolved to master song-learning,
will also yield insights into this question.
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remarkable record of scientific achievement. Mainly bec�use, at the
heart of it, is this truly collegial concept-to provide maximum
incentive for the carefully selected and highly gifted individuals
gathered here to relate to their fellow scientists across many different
specialties of knowledge and styles of critical thinking. Whether there
is any sense to having an institution of this kind at all depends on the
extent to which "colleague-iality" is protected, fostered, and encour
aged. This concept bears directly on our style of recruitment, on
career advancement plans, on the identification of areas selected for
emphasis in research, and on almost every other aspect of day-to-day
life at the University.
On a very personal level, I might describe myself as in a state of
transitional reconstruction - after a leap from the laboratory bench
to the board room - and wondering how to apply experience in
scientific scholarship to organizational leadership. However, I have
been confirmed in the belief that the inherent structure of The
Rockefeller University lends itself to a president who has personally
experienced the stresses, tedium, and thrills of the scientific pursuit.
Exciting about this environment is the responsibility that it places on
the president to fit into a collegial framework, to be sufficiently
informed or educable to enter into critical judgments about the wide
diversity of research in progress, to help bring people together from
different parts of the network, and to participate in the critical
dialogue that is the substance of scientific progress. Most of the people
at the University work in areas that are familiar to me and that I care
deeply about. This heightens my sense of the unparalleled opportunity
offered here for intellectual adventure and human service.
Scientific research is one of the most enthralling pursuits that can
occupy the human mind, and those of us who can dedicate our
lifework to it are privileged indeed. But the private excitement of
discovery should not obscure the enormous public stakes of the
enterprise. What we learn today about the structure of DNA and of
cells and how these are knit together in a functioning organism will
be indispensable tomorrow for what is indeed a war against pain,
disease, and death.
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Scie!ltific Direction

Manifestly, I have not returned to Manhattan to chart major changes
in institutional trajectory. Rather, I would aver that the University
can best perform its social function by consolidating its scientific
interests to hew more closely to the course implied in its original
name. This orientation is consistent with the goals and priorities
articulated by the preceding administration with our faculty and the
University Board of Trustees. Nonetheless, constant reexamination of
goals, priorities, and performance is an obligation of any institution
in the present climate of skepticism and inquiry about our entire
social fabric.
Our motto, pro bono humani generis, has its most direct application
in the discovery of health-saving, death-combating knowledge. Its
most obvious exemplification is in clinical research applied to the
development of drugs and vaccines. But these publicly acclaimed
advances are not the products of a static, stereotyped system of
preplanned discovery and invention. They are the fruits of a multi
dimensional, dynamically changing structure- the complex tissue of
health science and technology. Health progress must be informed by
scientific insights from an unpredictable variety of fields, and then
sometimes it leaps forward by purely empirical discovery. The basic
sciences have their own dynamics and are often energized by new
puzzles from the world of practice.
I am often asked whether the renewed consolidation of our
institutional identity with health research means that every professor
should make an immediate contribution to health applications. "No,"
I must reply, "that would soon be self-defeating." But we must design
and maintain an institutional structure that as a whole will make the
most effective contribution to both the underlying basic sciences and
their applied fruits. Each new appointment should be scrutinized for
its contribution to our collegial effort. In bringing a person here, we
should ask whether there is an advantage to the institution's entire
program that would socially justify the stresses and costs of moving
people from place to place. The excellence of a scientific work viewed
in isolation is thus an important, but not an exclusive, criterion.
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As I have already noted, most of the nation's larger, more complex
institutions-in order to reconcile the conflicting demands of their
established constituencies-find it difficult or impossible to identify
their fundamental goals and to design evolutionary structural changes
that will make them functionally most effective in meeting their own
aspirations. The Rockefeller University is a uniquely modern insti
tution, in that it was thoughtfully and consciously designed at its
inception and redesigned, with equal care, at several historic transition
points. It is true that in adopting the title University, the institution
ran some risk of simply inheriting a trunkful of traditions rooted in
the history of academic life generally, not all of which are pertinent
to its own goals and capabilities. But an advantage deriving from the
change is that our students and faculty have better access to the
mainstreams of career opportunities and, in turn, we can more readily
recruit from external sources. Since 1901, partly because of the
inspiration supplied by the success of The Rockefeller Institute,
biomedical research has grown enormously, and we cannot afford to
be isolated from the extensive efforts being made at many other kinds
of institutions throughout the world.
From time to time, the question has been posed, quite correctly:
In the light of the overall growth of research capability, what now is
the special role of The Rockefeller University? The manifest answer
is, as it has always been, the standard of excellence set by its faculty
and students. To continue to meet that standard requires a flow of
public and private resources that entails unremitting struggle to
sustain. To justify that flow requires a vision of inspiration and
organization, a design to meet the goal of the advancement of science
for health.
The main elements of scientific direction are, on the one hand, the
identification of research opportunities and of the superlative individ
ual competence needed to exploit them. On the other hand, there are
the institutional responsibilities for nurturing that competence, both
materially and morally, and for facilitating the mutual criticism,
communication, and collaboration that make an institution more than
a "boarding house of scholars." With respect to both of these elements,
I repeat that our present institutional structure offers a unique oppor
tunity for leadership. We are less encumbered than any comparable
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organization in the capacity for self-management and adaptive
change, after thoughtful consideration, to improve the efficiency and
efficacy of scientific research. Since the beginning of the century, the
fruit has been a continuing harvest of the most consequential and
highly regarde.d discoveries, impressive in absolute terms, and surely
preeminent in the yield per dollar invested.
At the present time, the flow of federal funds for the support of
research is essentially at a plateau, but an enormous one-so large as
to have discouraged the private sector from sharing in the support of
Messenger ribonucleic acid (mRNA) is the
information carrier that transmits the mes
sages encoded in the cell's genetic data
bank, deoxyribonucleic acid (DNA). The
messages instruct the cell's machinery to
make - in the amount needed, when
needed - the proteins basic to all life
processes. But how is a particular message,
stored in one of the thousands of genes
which constitute an organism's master
code, "expressed" precisely when re
quired? What switches genes on and off?
Scientists have made great progess in
understanding the mechanism of gene
expression in bacteria. The DNA in a bac
terial cell (prokaryote) is not bound within
a nuclear membrane, as is the DNA in the
eukaryotic ("true nucleus") cells of hu

mans and other higher organisms. In bac
teria, the transcription of a genetic mes
sage into a molecule of RNA, followed by
conversion into a protein, is a direct proc
ess. The primary RNA transcript, or copy,
is the messenger RNA. As soon as the new
RNA molecule begins to be transcribed, it
is engaged by cell organelles called ribo
somes, which then begin to make protein.
Not so, scientists have found, when it

comes to gene expression in the larger and
more complex eukaryotic cell. Only re
cently have molecular biologists begun to
identify the steps in the intricate process
by which eukaryotes make messenger
RNA, a key event in normal and abnormal
cell growth.

Years ago it was found that DNA in
eukaryotic cells produces RNA molecules
substantially larger than messenger RNA.
James E. Darnell, Jr., a Vincent Astor Pro
fessor at the University, and his associates
have spent more than 15 years deciphering
the meaning of these large nuclear RNA
molecules. Their experiments have pro
vided much of the evidence for the surpris
ing conclusion that the large RNA mole
cules in the cell nucleus are the precursors
of smaller messenger RNA molecules in
the cell cytoplasm. The primary RNA tran
script of the DNA code in the nucleus of
the eukaryotic cell is not used directly as
mRNA. Instead, the long, ribbon-like pre
cursor molecules are cut - by enzymes
- into smaller pieces that undergo certain
chemical modifications. Then, as shown in
the diagram, some of these RNA segments
are spliced together to form messenger
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experimental laboratory research. Ever-increasing burea!lcratic har
assments aside, it is true that federal funds can be obtained for a wide
variety of specialized projects. But this government support is pri
marily for categorical disease-related research. What is often neglected
in federal funding is the need for continuity in long-range research
programs and their meaningful integration into an institutional effort.
RNA, which directs protein production in
the cytoplasm.
This new understanding of mRNA for
mation in eukaryotes makes it possible to

DNA

Precursor

RNA

define in biochemical terms how and at
what level gene expression is regulated in
humans and animals. Beyond that lies one
of the prime goals of biological science
today - the regulation of cancer cells.
The differences between messenger
RNA formation in prokaryotes and in eu
karyotes also has profound implications
for the study of evolutionary biology. It
has been assumed by many that eukary
otes evolved from prokaryotes. But the
findings of Dr. Darnell and others strongly
indicate that a simple sequential evolution
of eukaryotes from organisms like today's
bacteria did not occur. If this is true, Dr.
Darnell suggests, "then it seems not only
possible but logical that the basic rules of
genome organization might also differ be

tween present-day prokaryotes and eu
karyotes." (The genome is the complete set
of hereditary factors encoded in the cell's

mRNA

DNA.)
All of this may have an important
bearing on future research. Dr. Darnell
concludes, "If the molecular basis of eu
karyotic gene regulation is to be_ explained
in relation to developmental biology or
cancer biology or endocrinology or many
other topics, it is at least possible that we
cannot rely on bacterial models but must
again solve the molecular control mecha
nisms of eukaryotic genes."
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This is compounded by th� innumerable, subtle counter-incentives
that constantly chip away at that integration. Private support is thus
both indispensable and a means of leverage. By assuring the conti
nuity and the integration essential to productive research, such sup
port can assure the most creative utilization of the federal monies that
constitute almost half of our operating budget. This ratio is appropri
ate; there would be great perils if it were to increase substantially.
In the years ahead, it will be one of my central responsibilities to
reexamine the roots of scientific creativity. I have no easy prescription
for fostering such creativity. In my own experience, however, nothing
equals the confrontation of an eager, trained curiosity with the
established doctrines and with the new findings of other disciplines.
In such fresh encounters, new questions arise. The traditions and
structures of our University offer unexcelled examples and new
opportunities for this kind of discourse; but there is still much to do
to bring this approach to its fulfillment. We may even have lost
ground in recent years because of the expansion of the campus and
the disappearance of the venerable Welch Hall dining room, which
furnished such a congenial setting for interdisciplinary exchanges. To
find a creative functional heir to that tradition is one of my immediate
preoccupations.

Contemporary Challenges in Health Research
In 1901, bacterial infections-the great plagues-were the most
serious challenges to health. Following on the work of Pasteur and
Koch, the Institute was an important encampment of "The Microbe
Hunters," so called by Paul de Kruif in a book that inspired a
generation of medical scientists (including myself). Developments in
sanitation, vaccines, antibiotics, and nutrition have given our people
the most startling improvement in public health experienced in his
tory, and those diseases no longer top our list of concerns. But these
same successes have raised public expectation to a level almost
impossible to satisfy in other fields, although the development of
vaccines for the important killer viruses has been a major accomplish
ment of the last 25 years.
Today, our public health concerns number heart disease, psychi
atric disease, and cancer as the chief causes of severe disability and
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death, and other virus infections and degenerative diseases, such as
arthritis, as grave hindrances to a happy life expectancy and produc
tive employment. The hunting of microbes was a relatively easy
task-the villain was a well-definable alien species. We had but to
track and kill it, or at least check its spread. For today's major health
threats, the problem is lodged within our own bodies. We face the
subtle challenge both of achieving a deeper understanding of the
human organism, far more complex than any bacterium, and of
refining the very process of research involving human beings to
change our own physiology in order to improve our health. Of course,
we generate many health problems through our individual life styles.
The issues of diet, exercise, smoking, and alcoholism are too familiar
to bear repetition. Even so, we do not properly understand the
mechanisms or precise efficacy of changes of life style as they affect
health, and the very accomplishment of more hygienic styles of living
is a challenge to the behavioral sciences.
There is no lack of challenge to physiology, either. We really do
not understand at all the perceived gratification that leads people to
smoke, and we may well be on the wrong track in popular myths
about the drives in alcoholism. Studies of the mechanism of action of
opiates on the brain have just recently excited an explosion of
discovery of previously unsuspected natural drugs in the brain, such
as the endorphins, that may also be the key to many other psychiatric
problems. The abysmal failure of most attempts to alter bad habits of
excessive eating, drinking, and smoking tells us that to have a real
impact on public health via "life style" will take a far more sophisti
cated insight into human behavior than moralizing about what is bad
for you.
Prevention of disease is surely our primary objective for today's
most serious health problems, simply because it is so difficult to effect
useful remediation of the human body once its parts have begun to
fail. Many specific environmental influences are now suspect in heart
disease and cancer, and a clearer delineation of the hazards to avoid
and of the specific dietary intake to encourage will add a badly
needed precision and efficacy to life-style admonitions. As I will
discuss in more detail further on, we also need more precise attention
to risk-assessment of chemical hazards in the environment to provide
credible direction to overarching policy choices in environmental
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regulation, which otherwise may paralyze the national economy. In
all likelihood, basic research will be even more cogent for these
questions than for the design of new means of diagnosis and treatment
of existing disease.
Besides the ,specific mechanisms of arterial disease or cancer, the
more general condition of aging points to the most fundamental
biological questions-why, for instance, are the life-spans of man
and mouse so different?-that touch upon the gravest aspects of the
human condition. To pursue these questions will require intense and
sophisticated interweaving of basic and clinical pursuits.
Research Priorities
At this University, it is important that we maintain ourselves at the
forefront of basic research in molecular and cell biology: those
fundamental areas of chemistry that are most closely connected with
understanding the structure and function of cells and the higher levels
of organization of molecules into cells, tissues, organs, and organisms.
We must also continue to explore the connections between behavior
animal and human-and the knowledge gained from studies at the
molecular and cellular level. It is a short step from this kind of science
to practice. We are becoming increasingly aware, for example, that
such basic biological mechanisms as communication between cells
and hormonal function must be better understood before we can deal
effectively with the crushing practical problems associated with global
human reproduction.
The University has a very strong record of significant contribu
tions to the field of parasitology, particularly in the understanding of
malaria and other major tropical diseases. (Some of this research is
reviewed on page 15.) Parasitic infections constitute the greatest
health problems in vast areas of the world. To sustain the strong
research base we have for meeting this challenge and to energize it
with the insights of molecular biology are concerns central to the
University's mission.
Tremendous opportunities have arisen in the last several years for
work that has a base in molecular biology on one side, involves
behavioral science on another, and can contribute directly to solving
the urgent problems of psychiatric illness. The University must follow
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up on these opportumties and recruit people who respond to the
potentialities of such broadly based research.
The reciprocal dependence of health research and clinical man
agement of disease is mirrored in the techno-political problems we
face in sustaining a healthy environment for our species. An expand
ing industrial society today inevitably spews out an unprecedented
volume and variety of new substances to which we are exposed in air,
water, foods, drugs, at the work place, and at home. Each such
product, whether a natural compound like nitrate or a synthetic
innovation like saccharin, poses an intricate scientific problem. What
are the laboratory tests that will enable us to predict the toxicity to
man of a given substance? And such knowledge would still be far
from providing the framework for deciding how much of a given
toxic exposure is an acceptable trade-off for an economic and social
benefit. We have only a handful of people who are even able to
communicate intelligently in the languages-scientific, technical,
economic, political--- used on each side of the discourse. There has
been a grave failure in our educational institutions in that they have
not grappled with how to educate more people to cope properly with
these kinds of issues.
The Rockefeller University would certainly be an ideal setting in
which to institutionalize the discipline of comparative toxicology,
which is the scientific approach to these problems. That is, how can
we use laboratory data on other species and field observations on
sample populations to predict and assess risks to a wider consuming
public? Such studies call upon all that we know of human genetics
and evolution, particularly with respect to comparative biochemistry
and physiology. They will require the use of the most sophisticated
techniques of analytical chemistry and studies of the metabolism of
particular substances in man.
The articulation of this new science with policy may demand more
far-reaching steps. In the end, political decisions will have to be made
involving participatory processes that are beyond the special ken of
the University. Nevertheless, we still have an important responsibility
to voice the consequences of alternative policy choices, applying the
best technique of rational analysis that we can muster. The viability
of an industrial economy, as well as our personal security as individ-
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uals exposed to environmental threats, is at peril in these public policy
choices.
In approaching the trade-offs to toxicity-which are inexorable
because the very act of breathing pollutes the environment-we need
new institutions where the academy can work more closely with
government, with private foundations, and with industry. Exploring
the most useful forms of such collaborations, particularly to exploit
the existing resources and respond to the needs of the metropolis, has
been an urgent and ongoing preoccupation for me.
The Outlook for Clinical Research

Before leaving the topic of research priorities, I would like to comment
on our Clinical Research Center, The Rockefeller University Hospi
tal. Since its creation in 1910, the Hospital has been an integral part
of this institution. The recent competitive renewal of the major clinical
research grant from the federal government attested to the great
national importance of the Hospital's programs, which span a wide
Thr�e years ago, William Trager, head of
the University's parasitology laboratory,
and James B. Jensen announced the first
continuous cultivation in a test tube of
Plasmodium falciparum, the parasite of
human malaria. This achievement-which
freed malaria research from its depend
ence on limited samples from human in
fections or on· the availability of owl mon
keys, the only suitable laboratory hosts
eliminated a major obstacle to scientists
seeking a vaccine against the disease that
claims more victims and lives around the
world than any other.
The culture method has now been ap
plied successfully to several parasite
strains from different geographical areas
and has also been used for tests of anti
malarial drugs. Most significantly, the dis
covery has made possible a broad new

range of biochemical and immunological
investigations by Dr. Trager and his col
leagues, and by investigators elsewhere
who are working against the background
of an alarming resurgence of malaria, par
ticularly in tropical and subtropical areas.
A good deal of this research is funded by
such agencies as the World Health Orga
nization, the National Institutes of Health,
and the U. S. Agency for International
Development. Doctors Trager, Jensen, and
Robert T. Reese have devoted considerable
time and effort to helping other laborato
ries - particularly in Asia, Africa, and
Latin America - to initiate and maintain
cultures of P. falciparum.
One of the most promising lines of re
search opened by the availability of con
tinuous culture techniques is related to the
protrusions that develop on the outer
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array of research efforts in the study of human diseases. More than
30 well-defined disorders, largely chronic and degenerative in nature,
are under investigation. Overall, they represent a major portion of
the disabling and lethal afflictions to which human beings are subject
and for which we have yet to find wholly satisfactory means of
prevention and treatment. Working with the senior faculty, adminis
tration, and trustees, the Hospital's physician-in-chief, Dr. Attallah
Kappas, bears principal responsibility for appraising opportunities
for new research initiatives that will enhance the strengths of this
superb facility.
We are facing some redefinition of what constitutes clinical re
search these days. There was a time when the observation of disease
at the bedside was, by itself, a very important part of medical progress.
The clinical scientist still relies on direct contact with individual
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patients, but more and more ofthe studies central to clinical research
are done on tissue and fluid samples. This requires seeing patients for
short intervals, rather than being directly engaged with them over a
very long period of time. Such an approach has important practical
implications for our Clinical Research Center that we are just begin
ning to explore in detail.
The Hospital has always been noted for a broad range oflabora
tory research that has complemented direct work with patients. Today,
more than ever, we are seeing the Hospital as a base for research
projects-involving human subjects-a very large measure ofwhich
is not done in an immediate clinical context. You might describe the
Hospital as the summit of an iceberg of research that reaches deep
into basic science. For example, in research on diabetes and other
diseases, the investigators obtain samples from patients and carry out

membranes of red blood cells (erythro
cytes) infected with the human malaria
parasite. These "knobs" (visible in electron
micrographs, like the one shown here, as
inverted, cuplike plaques just beneath the
membranes) occur only in erythrocytes
harboring older parasites and are the por
tions of the infected cells that adhere to
the endothelial cells of the capillaries
imbedded in the heart and other organs,
where the disease takes hold. By chemical
and immunological studies, Dr. Araxie Ki
lejian showed that the material in the
knobs is antigenically distinct from normal
red-cell membranes and is clearly of par
asitic origin. Susan G. Langreth and Dr.
Reese then discovered that owl monkeys
made immune to falciparum malaria pro
duce antibodies to the knobs. Most re
cently, Dr. Langreth has made the intrigu
ing discovery that each of three different

strains of the human parasite that had
been in continuous culture between one
and two years developed variants that do
not form knobs in the erythrocytes they
infect. This was the first report of a change
in P. falciparum after extended test-tube
culture.
Work is now in progress to determine
the relative disease-producing potential
(pathogenicity) of "knobless" and
"knobby" lines of the human malaria par
asite. Does knoblessness reflect a change
in the pathogenicity of the parasite, which
can be tested in experimental animals? Do
other changes as yet undetected occur in
the parasites after extended cultivation?
The investigators do not yet have the an
swers. However, they do know that the
answers will be especially relevant to re
search on possible malarial vaccines and
to drug screening and chemotherapy.
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some protracted observations of individual patients, but_spend most
of their time in the laboratory testing biochemical approaches to the
treatment of disease. This is, in part, a result of new developments in
scientific technique. If you can maintain human cells in the test tube,
you can test the effects of chemicals on these cultures, rather than
within a patient.
Since we need a certain minimum scale of activity for efficient
operation of the Hospital, we are also actively engaging the interests
of neighboring institutions in clinically related studies. We are happily
situated in a neighborhood of medical institutions-The New York
Hospital and Cornell University Medical College, the Sloan-Kettering
Institute for Cancer Research and Memorial Hospital for Cancer and
Allied Diseases-and have numerous possibilities for matching our
own intellectual style and skills in research to the diverse problems
and resources of our neighbors. This framework of cooperation means
our investigators can undertake collaborative work at these larger
hospitals with their highly advanced technology for patient care. In
return, their staffs will have access to the different technical resources
of our Clinical Rese�rch Center and to the, in some respects, more
efficient and closer surveillance of patients it makes possible. This
growing collaborative effort is of particular value in guiding the
research and education of some of our younger scientists who hold
clinical research fellowships. It gives them a much wider variety of
experience than they would encounter within our Hospital alone. In
like fashion, our proximity to the Payne Whitney Psychiatric Clinic
at The New York Hospital has given us the opportunity to explore a
range of options that will further research on the biochemical aspects
of schizophrenia, depression, and other psychiatric disturbances.
Postdoctoral Training

This brings me to the University's traditional educational role-the
support and preparation of gifted young people for scientific careers.
From the very beginning , this institution has functioned as a focal
point for individuals from all over the world who are seeking to
deepen their experience in research by working side by side with
senior colleagues who are recognized leaders in their fields. Thousands
of gifted investigators have passed through our laboratories and have
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moved on to important rese�rch posts in other institutions. Many of
them return from time to time to share with former colleagues the
fruits of their own investigations or to carry out some collaborative
project in one of our laboratories. The impact of this continuing
venture in postdoctoral education on the quality of biomedical science
in this country is one of the University's major distinctions. It is a
fulfillment of the hopes expressed at its founding, at a time when
aspiring scientists had to seek their training in institutions abroad.
Everything I have said about the structure and style of the
University with regard to research applies to its educational activity.
The younger scientist taking his first step in a research career is
received as a colleague in every sense of the word, and is free to move
beyond his own laboratory to seek whatever advice or guidance he
needs in building his own base of knowledge and research expertise.
Graduate Study Program

This is, to a large extent, equally true of our graduate program. A
memorable experience that capped my first year in office was par
ticipating on June 6, 1979, in the awarding of the Ph.D. degree to 28
graduates. This was the University's 21st Convocation and the 25th
anniversary of its assuming the status of a graduate university.
Having recently attended convocations with audiences in the tens
of thousands, I was impressed by the focus on individual talent and
performance that dominated our modest ceremony. We were able to
present each candidate and review very personally his or her accom
plishments and high promise. There is no doubt that these people will
be the leaders of medical science, and that each one has the chance
to reshape the way in which we view the world and how we adapt to
live in it. Nothing could better exemplify the special quality of this
institution.
Operationally, the graduate program takes advantage of the exist
ing edifice of the research institute. The students enter a flexible
tutorial program that encourages initiative on their part and places a
heavy emphasis on research experience, which the University is so
uniquely structured to provide.
All of us- and Dean James G. Hirsch and his associates in
particular-put a great deal of time and expense into student selec-
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tion. By bringing applicants to the campus, we can see them as
individuals and evaluate their maturity and creativity. The very low
dropout rate (about 5 percent) justifies the effort. In a closely knit
campus community with a strong sense of common goals, the impact
of I 00 brilliant young people from all over 'the world is provocative
in the highest sense, both intellectually and socially.
After just a quarter of a century, the University is justified in
viewing its educational "experiment" as successful in its objective of
producing leaders in science. This is indicated by the outstanding
recognition given to it by scientists and educators throughout the
world, as well as by the results of independent national evaluations of
the quality of doctoral graduates in the biomedical sciences, all of
which place the University's alumni at the top.
Equally impressive are the accomplishments of our alumni. Of

The skin is the largest organ of the human
body, accounting for three to five percent
of its total weight. Because this cutaneous
tissue is a remarkably resistant and tough,
yet pliable, membrane, we tend to view it
primarily as a passive barrier that blocks
harmful materials from entering the body
and prevents essential body substances
from escaping. But increasing concern
about the possible toxic effects on human
beings of many chemicals in the environ
ment has focused increased scientific re
search on structures, like the skin, that
function at the interface of the body and
the world around it.
One of the scientists contributing to
this research is Attallah Kappas, physi
cian-in-chief of The Rockefeller University
Hospital and head of the metabolism
pharmacology laboratory. A major inter
est of the laboratory is environmental bio
medicine, particularly clinical studies of

human disorders caused by drugs and en
vironmental chemicals. Research by Dr.
Kappas and David Bickers, formerly a
Rockefeller University Scholar in Clinical
Sciences and presently chairman of the
Department of Dermatology at the Case
Western University School of Medicine,
on coal-tar products and cutaneous tissue
suggests the import of recent findings on
the role of the skin.
Coal tar, a by-product of the gasifica
tion and distillation of coal, is widely used
in the treatment of dermatologic diseases,
particularly such chronic skin disorders as
eczematous dermatitis and psoriasis. Coal
tar contains a number of chemicals called
polycyclic aromatic hydrocarbons, includ
ing 3, 4-benzo [a]pyrene (BP). BP is a pre
cursor of several potent chemical carcino
gens found in the environment; it is known
to evoke tumors in the skin of experimen
tal animals and, perhaps, also of humans.
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325 graduates surveyed in the summer of 1978, 76 (23 percent) had
reached the rank of full professor or the equivalent, 85 (26 percent)
were associate professors, and another 26 percent had become assist
ant professors. About 95 percent of all graduates were engaged in
full-time research and teaching. Two graduates have won the Nobel
Prize. In reading these figures, one should bear in mind that our
alumni are, on the average, only a decade beyond completion of their
graduate work.
I strongly agree with the well-established policies of our graduate
program-that it should continue to operate according to the prin
ciples and scale that have governed it from the start. Our most
pressing needs for educational innovation relate to the integration of
scientific and medical interests. Our current response to this concern
is the joint M.D./Ph.D. program with Cornell University Medical
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Coal-tar solution was applied to the skin and 24 hours later
the site was biopsied. Skin homogenate was prepared and
AHH activity determined.

Studies in experimental animals suggest
that
aryl
hydrocarbon hydroxylase
(AHH), an enzyme present in skin, plays
an important role in metabolizing (chemi
cally transforming) polycyclic hydrocar
bons like BP into intermediate substances
that may directly trigger cancer. Dr. Kap
pas and his colleagues had demonstrated
earlier that AHH is present in the skin of
newborn human beings, and that enzy
matic activity is considerably increased by
the process of enzymatic induction when
cutaneous tissue is incubated in cultures
with a polycyclic hydrocarbon, such as
benzanthracene. With all this as a back
ground, Doctors Kappas and Bickers
thought it important to assess the AHH
induction effect of coal tar on patients
undergoing treatment for chronic skin dis
orders, for which this widely used drug is
employed.
Their studies showed, for the first time,
that the application of a coal-tar prepara-
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College, launched in 1972. This program is designed for a small group
of candidates who are strongly motivated toward a research career in
the basic or clinical biomedical sciences. The first Ph.D. degree in
this program was awarded in 1977, so a definitive evaluation is still
some time off, but the sheer quality of our registrants is a guarantee
of success. One objective indication is that this program was one of
the very few to get a renewal from the National Institutes of Health
with substantially full funding of our request. This gives us the time
to undertake a critical examination of the basic educational goals of
the effort and to seek approaches that will assure the maximum return
from the substantial investment of time and other resources.
Responsibilities to Young Scientists

The University seeks to provide a special place for the early devel
opment of careers in science with the expectation that the people

tion to the skin of patients with dermato
logic diseases induced AHH activity in
cutaneous tissue. This activity was from
two to five times greater than the enzyme
activity in untreated areas of the skin of
the same individuals. Of the several coal
tar constituents available for testing, BP
had the most potent effect. In related test
tube experiments, the investigators found
that enhancement of AHH activity also
took place when human skin was incu
bated with coal-tar solutions.
A third set of studies showed that use
of coal tar on the skin of experimental
animals causes induction of cutaneous
AHH and, after absorption through the
skin, also of AHH in the liver. Recent
studies in humans confirm that when coal
tar is applied to the skin, liver metabolism
of drugs and other chemicals is altered

substantially.
The data reinforce prior evidence that
human skin has enzymes capable of re
sponding to environmental carcinogens
and locally applied drugs and of convert
ing them into reactive metabolic products.
Doctors Kappas and Bickers conclude that
such metabolic activity may be one of the
important determinants of the pharmaco
logical potency of many drugs. It may also
be a critical factor in carcinogenic and
toxic responses to environmental chemi
cals, not only in the skin but also in other
tissues, after percutaneous absorption. As
more information about enzyme activity
in the, skin accumulates, science may have
to credit the body's largest organ with
being a far more active part of its meta
bolic machinery than traditional views

suggest.
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whom we have recruited wi�l find important research positions, not
just jobs, elsewhere. But there have been many changes in the
environment for science. We no longer live in an era where infinite
growth is the implicit agenda. Problems with the overall level of
science funding in this country, and the fact that only a small fraction
of approved grant applications is actually funded, are very discour
aging and tend to push people to aim for only safe targets. In fact, the
academic market for most doctoral graduates has shrunk, as have the
resources available for their training. This, in turn, reduces the
mobility from one center to another that is so important for the
vitality of science.
Having undertaken the responsibility of a productive and trans
forming role in dealing with scientific talent, we have to think very
carefully about the careers of our people. At one level there is the
eternal issue of quality control, to insure that the people we recruit
warrant the investment entailed in simply having them here, and that
they will make the most effective contribution to our research pro
grams. We also have to be careful about justice to them, primarily in
being sure that they are fully aware of what the world is like, and
what our own local world is like. We must plan with them the
optimum timing of their entry and, for most of them, their departure
at times and in ways most appropriate to their career development.
That very few long-term positions become available and that these
are likely to be filled on the basis of a national search has always
prevailed here, whereas at many other institutions it has become a
reality fairly recently. What we owe our young fellows and faculty is
an adequate opportunity to prove themselves and to develop their
own capabilities and intellects to the point at which they can further
their research objectives. Wherever appropriate, we foster indepen
dence to assure that their work is fundable by indispensable research
grants at the time they move to other positions.
Material Resources

To this point, my report has focused on the importance of our work
and the task of communicating and shaping that work to the best
interests of the human purposes we ultimately serve. But there is a
complementary task-a material one-of matching our plans and
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operations to a realistic model of the resources available.
The concept of collegial effort, pro bono humani generis, was
basic to the motivation of the Institute's founder. In 1901, John D.
Rockefeller, Sr. provided the financial base, which, with subsequent
additions from other family sources, enab,led it to operate entirely
from endowment income until the 1950s. By the early 1970s, however,
it became evident that the scope of the work of the University and its
importance to society had grown beyond the point where it was either
practical financially or appropriate in principle to depend on a limited
base of private support. If the University is to continue in the forefront
of the life sciences and as a major contributor to the improvement of
the human condition, then it has the obligation to develop future
support from an entirely new constituency of private donors. We can
best earn the confidence of these prospective supporters by adhering
to the core principles of this coherent research community.
One other observation is pertinent in this connection. A glance at
Chart 1, showing the sources of University income, reveals a steady
increase in government grants since it was decided to seek outside
funding. Such support is absolutely indispensable and, in fact, gov
ernment grants account for almost half of our annual operating
budget. However, as I noted earlier, it is predictable but lamentable
that this level of federal involvement inescapably comes to be asso
ciated with a frustrating degree of centralized management by the
government. Much of this funding is aimed at the "purchase" of
specified research results, neatly packaged in "projects." At its incep
tion, the federal support of biomedical research, �dministered pri
marily through the National Institutes of Health, reflected ideals
similar to the University's and admirably supported major innova
tions and discoveries. But the project grant system is now run in ways
that, however well-intended, sometimes threaten to disintegrate insti
tutions, to discourage the confluence of creative ideas, and to erect
serious obstacles to the collaboration of basic scientists in a wide
variety of clinical applications.
In the long-term planning for the University's financial future, we
cannot forget that one of the most important functions of a privately
endowed institution is to offer an effective counter-example to the
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services-rendered approach to research support. We have i? mind the
investment of venture capital in the identification of creative individ

uals and of collegial frameworks for reaching the same ends. The
central ethos of this institution is the responsibility of making up our
own minds-independent of erratic fluctuations in external attitudes
and policy- about the areas that warrant careful nurturing and
support, sometimes over fairly long periods.
A Financial Projection

In appraising the University's financial situation, I must affirm right
at the start that we may congratulate ourselves in being far closer to
equilibrium today than are most other private academic institutions.
This is largely due to the foresight of my predecessor, Frederick Seitz,
and the University Board of Trustees in husbanding the University's
resources so carefully and launching the first fund-raising effort in
our history. There has been a decade of effort to make the University
fiscally stable and to preserve its distinction. The most painful ad
justments are already behind us. These have included a significant
reduction in non-faculty staff from a peak of 1,033 in 1971 to slightly
more than 890; a leveling-off in both tenured and non-tenured faculty
at about 450 after an almost threefold growth since 1955; a concerted
effort to hold down costs; and an ongoing process of reexamining
institutional priorities.
With hard work and moderate good luck, we have a planning
framework for vigorous survival. We have already brought our cur
rent expenses budget into balance (Table 1), and we are projecting a
balanced overall budget (including capital expenses) within a few
years. But, as Chairman of the Board Patrick E. Haggerty has stressed,
this projection is based on the "conviction that fund-raising from
diverse private and public sources must be an intensive continuing
effort open to periodic adjustment of goals. The University has faced
up to the reality of the times-that to maintain its high level of
achievement, it must sustain indefinitely the effort of the past decade
to attain greater financial independence."
Before exploring more fully the scope of our fund-raising com
mitment, I think it is necessary to answer a question that may be
prompted by the picture I have presented of an institution that is

The Rockefeller University

28

consolidating its goals and stabilizing its growth in size and numbers.
"Why do you need more money if your policy is to hold to ihe present
size of the University?" There are two answers to this question: one
to be found in an analysis of where our money goes and the other in
a statement of our basic endowment needs. ,
Where the Money Goes

A glance at Chart 2 shows that 65 percent of our current expense
dollars are direct expenditures for our research and education pro
grams. That is as it should be, because we are really talking about the
support of first-class scientific work by people of the highest caliber.
The fact is that a certain amount of renovative growth has to be built
into such a community to sustain vitality. Even though we do not
plan to increase the number of full professors, an inherent growth of
"technicality" at this University is related to the complexity of the
equipment we use and the sophistication of the work we do. This is
not numerical growth, but it is definitely a cost growth. Similarly, in
an institution where there is a constant coming and going of investi
gators, particularly at the non-tenured rank, we need the resources to
regenerate the system constantly, even though, over the course of
time, there are no major fluctuations in the overall scientific popula
tion.
A related figure in Chart 2 is the 13 percent that the University
expends for the operation and maintenance of its physical plant. Over
half of this amount is spent for energy. It is inherent in an institution
such as ours to be energy-intensive for the operation of instruments,
to keep laboratories working around the clock. Controlled environ
ments, which require high usage of energy, are mandated by govern
ment regulations/as well as necessary for stable results in experiments
with animals. With the onset of the fuel crisis, the impact of energy
costs has been increasingly aggravated and, even as I write, threatens
to upset budget balances.

Strengthening Endowment
The energy problem is also involved in the second answer to our
question about financial needs-we need additional resources to
repair the depredations of our endowment. These stem from all the
fiscal and economic blows we share with other non-profit institutions
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and that are built into the American economy, inflation�above all.
For example, there was a small, absolute rise in endowment income
from $8.9 million in 1969 to $11.4 million in 1979. However, this
seeming improvement quickly fades if we consider that the income
would have had to be _on the order of $15 million in 1979 to match
the purchasing power of $8.9 million in 1969. Similarly, the market
value of endowment funds in 1979 was over $201 million, approxi
mately the same as in 1969. But to match the purchasing power that
$201 million had in 1969, our endowment today would have to be
over $350 million.
As I have already indicated, though not discounting the very real
threat of the unforeseeable, we can look ahead to achieving financial
balance in the near future. We have made carefully considered
projections, and we �pdate them on both quarterly and annual
schedules to measure our performance against our goals. But the
projections for a decade are sensitive to a number of assumptions that
only the march of events can validate.

Grant from the Rockefeller Brothers Fund
The best financial news of this academic year is that the University
has been awarded a five-year grant of $15 million by the Rockefeller
Brothers Fund, with future provision for an additional $7.5 million if
certain conditions are met. Without this generous contribution, in
response to a comprehensive plan submitted by Dr. Seitz in October
of 1977, it would be extremely difficult to foresee a balanced budget.
The unrestricted grant of $15 million has betn allocated to the
University's capital endowment. To receive the challenge grant of an
additional $7.5 million, the University must satisfy two conditions by
December 31, 1986. The first is that the institution raise $10 million
in new endowment in addition to the RBF basic award of $15 million.
The second is that we match the additional $7 .5 million fund, dollar
for dollar, by contributions to endowment from other private sources.
The RBF has also stipulated that funds, estimated at about
$500,000 annually, will be available to the University, Memorial
Sloan-Kettering Cancer Center, and The New York Hospital-Cornell
Medical Center for joint or cooperative projects initiated between this
year and the end of 1983. I believe this is a highly constructive
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mechanism for financing a number of worthwhile interinstitutional
ventures, and a joint steering committee is working hard on tangible
proposals.
In fulfilling its special responsibilities to one of the organizations
that historically has been of strong interest to the Rockefeller family,
the RBF indicated that it contemplates making no additional large
capital grants to the University. This does not preclude the future
consideration of project requests in the light of the Fund's evolving
program interests.
We are all indebted to the RBF for this inspirational demonstra
tion of faith in the future of The Rockefeller University as a major
source of scientific innovation and medical progress. As magnificent
as the grant is, we know it does not solve all our financial problems.
However, the RBF award will serve as the cornerstone of a new and
intensive plan, which responds to the challenge and calls for raising
a total of $150 million from private sources within the next ten years.
The new plan-shown here in summary form (Table 2)-incorpo
rates all of the University's prime objectives, and aims to achieve
them before the end of the next decade. A significant component of
this plan is the University Associates Program, which will be instituted
in 1979-80. This replaces and expands the current Annual Giving
Program. It will broaden the base of constituency support for our
annual operating expenditures.
The task before us is not to be taken lightly. But we have a
�ompelling
message and a sound plan to communicate to prospective
supporters, and the confidence that comes from knowing we are
proposing investment in an enterprise that has always been productive
of public good.
An Afternoon to Remember

This has been a hectic year, a rewarding year, a full year. Even in so
short a time I have many rich memories of this unusual community
of which my family and I are now enthusiastic citizens. And we are
deeply impressed by the spirit of cooperation and the individual
concern shown by all members of the staff, whatever their area of
responsibility.
In closing this report, I would like to look back on one event that

TABLE 2

THE ROCKEFELLER UNIVERSITY
IO-YEAR DEVELOPMENT PROGRAM
ENDOWMENT
For People
20 Professorships
IO University Fellowships
10 Clinical Fellowships
20 Postdoctoral Fellowships
50 Doctoral Fellowships
Total for Endowment
OPERATING SUPPORT AND CAPITAL PROJECTS
For Fundamental Investigations, Including:
cell biology
the neurosciences
parasitology
reproductive biology
immunology
toxicology
For Clinical Studies, Including:
metabolic/genetic diseases
immunological diseases
biochemical psychiatry
cancer
environmental medicine
pharmacology
For Essential Facilities
Information/Computing Center
Modernization and Renovation of
Laboratories and Hospital
For General Operating Support•
Total for Operating Support and Capital Projects
Grand Total
• Includes University Associates Program

Millions
25
8
8
IO
20
71

35

20

5
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had deep personal meaning _for me, both as a scientist and a "fresh
man" president. On the afternoon of February 2, 1979, a seminar was
held in Caspary Auditorium that drew a large audience from the
campus, as well as scientists from a number of other institutions. The
occasion was the 35th anniversary of the publication in The Journal
of Experimental Medicine for February 1, 1944, of a paper by Oswald
T. Avery, Colin M. MacLeod, and Maclyn McCarty on the chemical
composition of the "pneumococcus transforming factor." The trans
forming factor, of course, was DNA, and the paper encapsulated
perhaps the most revolutionary biological discovery of this century_.:._
that DNA is the basis of heredity in all organisms.
Dr. Avery retired from The Rockefeller Institute for Medical
Research in 1948 and died on February 20, 1955, in Nashville,
Tennessee. Colin MacLeod served on the staff of The Rockefeller
Institute from 1934 to 1941, then became a professor at New York
University Medical School. He died on February 12, 1972, in London.
Maclyn McCarty is now a John D. Rockefeller Jr. Professor at The
Rockefeller University, having also served as vice president from
1965 to 1978 and as physician-in-chief of The Rockefeller Hospital
from 1960 to 1974. In fact, that February seminar was equally a
celebration in his honor.
Participating in the warm and spirited exchange of reminiscences
that enlivened the gathering, I felt again the excitement with which
as a new graduate of Columbia College venturing into research - I
first read that now-historic paper and sensed its unlimited implica
tions. It was the initiating impulse to my own scientific career. How
gratifying then, 35 years later, to be among my peers in this commu
nity, with the opportunity to help sustain a tradition and a style of
biomedical research that have no match.
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GIFTS AND GRANTS
On behalf of our faculty, graduate fel
lows, and trustees, I would like to express
our warmest thanks to the following do
nors who have contributed to the Uni
versity during the nine fiscal years since
the first comprehensive effort in our his
tory to broaden our base of private sup
port was launched.
The first list includes those donors
whose assistance is helping to fulfill the
goals of the University's overall Devel
opment Program. Since its inception in
1971, the Program's goals have empha
sized additional endowment and long
term operating support for basic research

in selected life sciences, for the clinical
programs of our Hospital, for professor
ships, and for predoctoral and postdoc
toral fellows�ips. Several major donors
also have aided the construction of our
new Laboratory Animal Research Cen
ter, a high-priority objective for which
the remaining funds are still being
sought.
The second list recognizes contribu
tors who have provided funds for general
operating expenses, as well as for ongoing
research and special University-wide
projects.

Donors to The Rockefeller University Development Program
INDIVIDUALS

Mr. Ralph E. Ablon
Mrs. F. David Anderson
Mrs. Vincent Astor
Mrs. Wentworth Bacon
Mr. and Mrs. Charles F. Barber
Mr. Philip Bard
Mr. Charles C. Bassine
Mrs. Ursula Baum
Mr. and Mrs. William Bernbach
Mr. Nicholas F. Brady
Mrs. Mabel Bright
Mrs. Walker 0. Cain
Mr. Ray F. Carmichael
Mr. and Mrs. Eliot C. Clarke
Mr. Clarence Coe
Mr. C. W. Cook
Mr. and Mrs. Donald C. Cook
Ms. Jessie Corr
Mr. Richard W. Courts
Mrs. Virginia C. Courts
Mr. and Mrs. Thomas G. Cousins, Jr.
Mr. Michel David-Weill
Eli Whitney Debevoise, Esq.

Mr. and Mrs. J. Richardson Dilworth
Mr. and Mrs. Barry W. Dress
Dr. and Mrs. Rene Dubos
In honor of Vincent du Vigneaud, M.D.
Anne E. Dyson, M.D.
Mr. Oscar Dystel
Mr. and Mrs. Albert Foreman
Mrs. Ann Haebler Frantz
Friends of the University-Anonymous
Dr. and Mrs. Harold Gershinowitz
Friends of Elsie Gilenson
Mr. and Mrs. William T. Golden
Dr. Donald R. Griffin
Mr. James Griffin
Mr. and Mrs. Patrick E. Haggerty
Mrs. Andrew Heiskell
Mr. Leon Hess
Mr. and Mrs. James T. Hill
Mr. and Mrs. Robert C. Hubbard
Mr. Denison B. Hull
Mrs. Virginia S. Hutton
Mrs. Lucretia Jephson
Dr. and Mrs. Mark Kac
Ms. Neva Kaiser
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Dr. Lindsley F. Kimball
Mr. Bruce W. Knight, Jr.
Mr. Fred F. Lester
Mr. and Mrs. Budd Levinson
Mrs. Tillie Lewis
Marjorie Lewisohn, M.D.'
Mr. and Mrs. John E. Lockwood
Mr. and Mrs. Dan W. Lufkin
Dr. and Mrs. Channing H. Lushbough
Mr. Louis Marx
Dr. and Mrs. Maclyn McCarty
Dr. and Mrs. Neal E. Miller
Mrs. Maurice Moore
Mr. Albert L. Nickerson
Mr. and Mrs. George D. O'Neill
Dr. and Mrs. Carl Pfaffmann
Mr. and Mrs. R. Watson Pomeroy
Mr. David Rockefeller
Mr. David Rockefeller, Jr.
Mr. Walter N. Rothschild, Jr.
Mr. Richard B. Salomon
Mr. and Mrs. Howard Samuels
Mr. Melvin R. Seiden
Dr. and Mrs. Frederick Seitz
Dr. Peter H. Sellers
Mr. Peter J. Sharp
Mr. and Mrs. Richard Shields
Mr. and Mrs. William K. Simpson
Mr. and Mrs. Herbert M. Singer
Mrs. Mary Detweiler Smith
Mr. and Mrs. James G. Stahlman
Miss Jennifer Stone
Mr. Robert G. Stone, Jr.
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